Abstract
The interface between the science of genomics and the law of protecting inventions has been fraught with controversy. This paper starts with a basic primer on US patent law followed by a review of the patent issues related to genomics discoveries, in particular, expressed sequence tags (ESTs). Particular focus is placed on the positions expressed by those within the National Institutes of Health and the US Patent and Trademark Office about policy questions and patentability issues for ESTs. The paper concludes with a report on the status of patent law issues related to genomics and discusses those issues yet to be resolved. Drug Dev. Res. 41:205–217, 1997. © 1997 Wiley-Liss, Inc.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
